It is shown that the performance of such a system is strongly dependent on the envelope of geometric parameters of the levitator. To study this dependence systematically, a thorough numerical model using the finite element method is developed. Both rigid and flexural radiating plates are considered. The effect of all important geometric parameters
on the resulting acoustic potential patterns is investigated. After successful experimental validation, in which particles of density ca. 1000 times higher than that of their surrounding gas (similar to 1 g/cm(3) versus similar to 10(-3) g/cm(3)) are levitated and translated, the model proves to be reliable in predicting the position JQ1 order as well as the force exerted on the levitated particles. (C) 2011 American Institute of Physics. [doi: 10.1063/1.3571996]“
“Aim: This
multicentre phase II trial examined the combination of gemcitabine and oxaliplatin in patients with advanced non-small cell lung cancer (NSCLC). The effect of sequence administration was randomized and pharmacokinetics (PK) assessed.
Methods: Eligible patients had stage IIIB or IV or recurrent NSCLC, no prior chemotherapy, World Health Organization performance status <= 2 and measurable disease. Treatment comprised: Rigosertib mw gemcitabine (1250 mg/m(2)) and oxaliplatin (70 mg/m(2)), each given on days 1 and 8 of a 21-day cycle. Patients were randomized 1:1 to the sequencing of the two drugs for the duration of their treatment. The primary end-point was response rate (RR). Secondary end-points included GW-572016 clinical trial progression-free survival (PFS), overall survival (OS), toxicity, PK and the effect of drug sequencing.
Results: A total of 46 patients were enrolled of whom 43 were evaluable for response. Overall 13 patients (30%) achieved a partial response, PFS was 4.2 months (95% CI 2.8-5.8 months), and OS was 6.8 months (95% CI 4.4-10.1 months). There was only one case of grade 3 neurosensory toxicity despite a median cumulative oxaliplatin dose in excess of 500 mg/m(2). No differences in clinical or PK end-points were observed between the two
different sequencing arms.
Conclusion: This oxaliplatin and gemcitabine schedule has shown activity in advanced NSCLC with modest toxicity. Neither clinical nor PK outcomes were influenced by the sequencing of these agents, although definite conclusions are limited by small patient numbers. The favorable toxicity profile of this doublet, in light of an encouraging RR, warrants its further investigation in NSCLC.”
“Background: During previous influenza pandemics, many deaths were associated with secondary bacterial infection. In April 2009, a previously unknown 2009 influenza A virus (2009 H1N1) emerged, causing a global influenza pandemic. We examined the relationship between circulating 2009 H1N1 and the occurrence of secondary bacterial parapneumonic empyema in children.